TIDMHZD
Horizon Discovery Group plc
19 October 2016
Horizon Discovery Signs Subscription Based Licensing Agreement
for Biomanufacturing Cell Lines
-- Horizon announces new bioproduction outlicense deal with a minimum value of GBP500,000
-- Novel licensing model allows early access over a 5 year
period to bioproduction cell line innovations as well as for
immediate use of Horizon's GS Null CHO K1 bioproduction cell line
for drug manufacturing
Cambridge, UK, 19 October 2016: Horizon Discovery Group plc
(LSE: HZD) ("Horizon"), the world leader in the application of gene
editing technologies, today announces a new licensing agreement
with an unnamed commercial partner ("Partner") for access to
Horizon bioproduction cell lines. The subscription deal, a first of
its kind for Horizon, is valued at a minimum of GBP500,000.
Under the terms of the license, the Partner will gain immediate
access to one of Horizon's cutting-edge engineered cell lines (CHO
SOURCE GS Null cell line), for an indefinite period of time in
order to manufacture their novel therapeutics. The Partner will
also gain early access to Horizon's programme of continuous cell
line innovation, enabling them to license, via the subscription,
any follow-on cell lines developed as part of the program at a 50%
discount within a 5 year period from signature. The minimum fee
will be paid up front, with a significant amount to be recognised
in FY2016.
The license deal follows an evaluation period initiated in Q4
2015 and reflects the confidence of the Partner that Horizon will
provide a number of additional cell lines over the next five years,
leading to significant efficiency improvements in their
biomanufacturing capability.
Dr. Darrin Disley, Chief Executive Officer, Horizon Discovery
Group, commented: "Horizon continues to be a disruptive influence
in the bioproduction arena, using technical and commercial
innovation to accelerate advancements in drug manufacturing. This
new announcement further validates our approach, with our Partner
demonstrating their confidence by making a five year commitment via
subscription model to the program. We look forward to making
further announcements in this area as Horizon continues its
momentum as a key player in the bioproduction space."
- ENDS -
Notes
About Horizon's Bioproduction Business
Protein therapeutics represent a significant share of the top 50
drugs globally and are increasingly present in developmental
pipelines. The provision and licensing of bioproduction cells for
their manufacture, however, can be cost prohibitive, especially for
smaller organisations, and are often tied to long-term
revenue-based licensing terms.
Horizon is a leading provider of precision engineered off the
shelf and custom CHO cell lines used for the manufacture of
biological therapeutics. The CHO SOURCE platform delivers a fully
engineered and characterised host cell line, ideally suited to the
manufacture of recombinant protein therapeutics. Horizon constantly
works to improve its bioproduction cell lines under a program of
continuous cell line innovation to ensure that cells delivered to
customers always provide the greatest efficiency and value
possible.
Horizon first out-licensed the CHO SOURCE cell line in 2015 and
several additional commercial licenses have been executed since,
driven by the combination of top tier innovation and disruptive
commercial licensing terms. Horizon's business model is focused on
securing significant market share and then using continuous
innovation to develop strong customer loyalty.
For further information, please contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
Numis Securities Limited (Joint Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
RBC Capital Markets (Joint Broker)
Paul Tomasic / Marcus Jackson
Tel: +44 (0) 20 7653 4000
About Horizon Discovery Group plc www.horizondiscovery.com/
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a
world-leading gene editing company that designs and engineers
genetically-modified cells and then applies them in research and
clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary
translational genomics platform, a highly precise and flexible
suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter
almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related
research services, almost all of which are based on the generation
and application of cell and in vivo models that accurately
recapitulate the disease-causing genetic anomalies found in
diseases like cancer. Horizon's commercial offering has been
adopted by c1,400 unique research organisations in over 50
countries as well as in the Company's own R&D pipeline to
support a greater understanding of the genetic drivers of disease
and the development of molecular, cell and gene therapies that can
be prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD". For more
information see www.horizondiscovery.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMMMGMRMGVZZ
(END) Dow Jones Newswires
October 19, 2016 02:00 ET (06:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2023 to Apr 2024
